ATHERSYS INC (ATHX) Stock Price, Quote, News and Overview
NASDAQ:ATHX - Nasdaq - US04744L2051 - Common Stock - Currency: USD
ATHX Quote, Performance and Key Statistics
0.1018
+0 (+3.77%)
The current stock price of ATHX is 0.1018 USD. In the past month the price decreased by -67.28%. In the past year, price decreased by -94.94%.
ATHX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About ATHX
Company Profile
Athersys, Inc. is a biotechnology company, which focuses on the field of regenerative medicine. The company is headquartered in Cleveland, Ohio and currently employs 24 full-time employees. The company went IPO on 2007-04-23. The firm is engaged in the discovery and development of therapeutic product candidates to address unmet medical needs in multiple disease areas. Its MultiStem (invimestrocel) cell therapy, which is an allogeneic stem cell product candidate, is its lead platform product and is in late-stage clinical development. MultiStem cell therapy includes treatment of critical care indications, neurological conditions, inflammatory and immune disorders, certain pulmonary conditions, cardiovascular disease, and other conditions. MultiStem cell therapy is manufactured from human stem cells obtained from adult bone marrow and these cells are alternatively obtained from other tissue sources. The company is conducting a Phase III clinical trial of MultiStem cell therapy for the treatment of ischemic stroke, referred to as MultiStem Administration for Stroke Treatment and Enhanced Recovery Study-2 (MASTERS-2).
Company Info
ATHERSYS INC
3201 Carnegie Ave
CLEVELAND OHIO 44115 US
CEO: William Lehmann Jr.
Employees: 24
Company Website: https://www.athersys.com/home/default.aspx
Phone: 12164319900.0
ATHERSYS INC / ATHX FAQ
What is the stock price of ATHERSYS INC today?
The current stock price of ATHX is 0.1018 USD. The price increased by 3.77% in the last trading session.
What is the ticker symbol for ATHERSYS INC stock?
The exchange symbol of ATHERSYS INC is ATHX and it is listed on the Nasdaq exchange.
On which exchange is ATHX stock listed?
ATHX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ATHERSYS INC stock?
7 analysts have analysed ATHX and the average price target is 5.61 USD. This implies a price increase of 5410.81% is expected in the next year compared to the current price of 0.1018. Check the ATHERSYS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ATHERSYS INC worth?
ATHERSYS INC (ATHX) has a market capitalization of 2.29M USD. This makes ATHX a Nano Cap stock.
How many employees does ATHERSYS INC have?
ATHERSYS INC (ATHX) currently has 24 employees.
Is ATHERSYS INC (ATHX) expected to grow?
The Revenue of ATHERSYS INC (ATHX) is expected to decline by -100% in the next year. Check the estimates tab for more information on the ATHX EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy ATHERSYS INC (ATHX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ATHX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ATHX, evaluating the profitability, health, valuation and growth aspects
- ATHERSYS INC (ATHX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ATHERSYS INC (ATHX) Sales and EPS estimates to see what analysts future expectations are.
- ATHERSYS INC (ATHX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ATHERSYS INC (ATHX) Insider and Institutional Ownership to learn about the owners and their transactions.
- ATHERSYS INC (ATHX) Stock Chart to make your own analysis
- ATHERSYS INC (ATHX) Latest news and press-releases to stay up to date.
Does ATHERSYS INC (ATHX) stock pay dividends?
ATHX does not pay a dividend.
When does ATHERSYS INC (ATHX) report earnings?
ATHERSYS INC (ATHX) will report earnings on 2023-11-13, after the market close.
What is the Price/Earnings (PE) ratio of ATHERSYS INC (ATHX)?
ATHERSYS INC (ATHX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.03).
ATHX Technical Analysis
ATHX Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to ATHX. ATHX has a bad profitability rating. Also its financial health evaluation is rather negative.
ATHX Financial Highlights
Over the last trailing twelve months ATHX reported a non-GAAP Earnings per Share(EPS) of -3.03. The EPS increased by 64.35% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -452.29% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
ATHX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to ATHX. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of 83.47% and a revenue growth -100% for ATHX